Clinical Trial: Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy

Brief Summary: A double-blind follow-up trial assessing the long term safety of Levetiracetam as per adverse events reporting, physical and neurological examination and vital signs

Detailed Summary:
Sponsor: UCB Pharma

Current Primary Outcome: Around 2 years of Safety assessment of levetiracetam via Adverse Events reporting, physical and neurological examination and vital signs

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: UCB Pharma

Dates:
Date Received: September 6, 2005
Date Started: July 2003
Date Completion:
Last Updated: November 25, 2013
Last Verified: September 2009